20/20 Biolabs, Inc.
AIDX
$0.60
$0.011.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 353.40K | 538.30K | 418.00K | 544.40K | 553.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 353.40K | 538.30K | 418.00K | 544.40K | 553.80K |
| Cost of Revenue | 290.50K | 407.90K | 272.90K | 379.90K | 388.00K |
| Gross Profit | 62.90K | 130.40K | 145.10K | 164.50K | 165.80K |
| SG&A Expenses | 1.35M | 912.70K | 814.20K | 808.00K | 801.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.80M | 1.45M | 1.22M | 1.35M | 1.33M |
| Operating Income | -1.44M | -912.80K | -800.20K | -808.90K | -772.20K |
| Income Before Tax | -2.17M | -1.31M | -825.50K | -802.80K | -764.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.17M | -1.31M | -825.50K | -802.80K | -764.60K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.17M | -1.31M | -825.50K | -802.80K | -764.60K |
| EBIT | -1.44M | -912.80K | -800.20K | -808.90K | -772.20K |
| EBITDA | -1.43M | -892.70K | -779.10K | -786.60K | -748.70K |
| EPS Basic | -0.20 | -0.25 | -0.17 | -0.17 | -0.26 |
| Normalized Basic EPS | -0.13 | -0.16 | -0.11 | -0.10 | -- |
| EPS Diluted | -0.20 | -0.25 | -0.17 | -0.17 | -0.26 |
| Normalized Diluted EPS | -0.13 | -0.16 | -0.11 | -0.10 | -- |
| Average Basic Shares Outstanding | 10.44M | 5.17M | 4.90M | 4.82M | -- |
| Average Diluted Shares Outstanding | 10.44M | 5.17M | 4.90M | 4.82M | 4.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |